Barry M. McGrath
Research Subjects
Barry M. McGrath has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Gregor Borut Ernst Jemec
Department of Dermatology and Allergy, PHOENIX Research Center Copenhagen University Hospital ‐ Herlev and Gentofte Gentofte Denmark
5 shared publications - John Robert Ingram
Division of Infection & Immunity, Cardiff University , Cardiff
5 shared publications - Bente Villumsen
Danish HS Patients' Association Soborg Denmark
4 shared publications - Aikaterini I. Liakou
1st Department of Dermatology-Venereology, “Andreas Sygros” Hospital, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece
3 shared publications - Alejandro Molina-Leyva
Dermatology Department Hospital Universitario Virgen de las Nieves‐Ibs. Granada Granada Spain
3 shared publications Bente Villumsen
The Patients' Association HS Denmark Copenhagen Denmark
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in JID Innovations
What people with psoriasis talk about online: Insights from a digital ethnography of lived experience
- 3 November 2026
- Published by Elsevier in JID Innovations
Open AccessWhat people with psoriasis talk about online: Insights from a digital ethnography of lived experience
- Open Access
- 10 October 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
The future management of HS : People with HS as partners
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with profound impact on quality of life. Increasing recognition of the patient's role as an active partner in their own care has transformed approaches to disease management, yet a conceptual framework for partnerships with people with HS remains lacking. To provide a comprehensive review of meaningful partnerships with people with HS across three levels: the individual, the patient community, and collaborative partnerships. For each level, we review existing evidence, illustrate barriers to meaningful involvement, present examples of successful patient involvement, and propose future directions. A narrative review of the literature was conducted. Barriers to partnership and future priorities were identified from both people with HS and clinicians' perspectives. At the individual level, structured communication strategies including teach‐back and shared decision‐making improve treatment adherence and patient satisfaction. At the community level, online patient networks provide peer support and health information. At the collaborative level, patient involvement in research design contributes to shaping policy and knowledge. Patient partnership in HS operates across multiple levels and requires tailored strategies to be effective. Engaging people with HS as partners is a respectful approach to create impactful, relevant research with the potential to improve outcomes and quality of care. A three‐level framework is proposed to guide future implementation.
- 10 October 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Open AccessThe future management of HS : People with HS as partners
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with profound impact on quality of life. Increasing recognition of the patient's role as an active partner in their own care has transformed approaches to disease management, yet a conceptual framework for partnerships with people with HS remains lacking. To provide a comprehensive review of meaningful partnerships with people with HS across three levels: the individual, the patient community, and collaborative partnerships. For each level, we review existing evidence, illustrate barriers to meaningful involvement, present examples of successful patient involvement, and propose future directions. A narrative review of the literature was conducted. Barriers to partnership and future priorities were identified from both people with HS and clinicians' perspectives. At the individual level, structured communication strategies including teach‐back and shared decision‐making improve treatment adherence and patient satisfaction. At the community level, online patient networks provide peer support and health information. At the collaborative level, patient involvement in research design contributes to shaping policy and knowledge. Patient partnership in HS operates across multiple levels and requires tailored strategies to be effective. Engaging people with HS as partners is a respectful approach to create impactful, relevant research with the potential to improve outcomes and quality of care. A three‐level framework is proposed to guide future implementation.
- Open Access
- 26 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (5) , 859-861
Patient and healthcare professionals’ perspectives on pain management in hidradenitis suppurativa: a quantitative and qualitative study
Patients with hidradenitis suppurativa experience frequent pain which affects mood, quality of life, relationships and physical activity. Surveys and focus groups revealed that dermatologists rank pain management importance more highly than pain specialists and healthcare professionals in primary care but that they lack confidence in managing it. This study highlights the need for improved pain management education for dermatologists, multidisciplinary care pathways and better coordination between dermatology and primary care to support patients.
- 26 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (5) , 859-861
Open AccessPatient and healthcare professionals’ perspectives on pain management in hidradenitis suppurativa: a quantitative and qualitative study
Patients with hidradenitis suppurativa experience frequent pain which affects mood, quality of life, relationships and physical activity. Surveys and focus groups revealed that dermatologists rank pain management importance more highly than pain specialists and healthcare professionals in primary care but that they lack confidence in managing it. This study highlights the need for improved pain management education for dermatologists, multidisciplinary care pathways and better coordination between dermatology and primary care to support patients.
- Open Access
- 18 August 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment
Background: This first part of the S2k guidelines is an update of the 2015 S1 European guidelines based on the structured assessment of clinically relevant topics by the panel of experts. It is complemented by Part 2, which deals with treatments. Objectives: These guidelines aim to provide the generalist with expert guidance regarding clinically relevant topics such as, for example, diagnosis, clinimetrics and comorbidities. Methods: The S2k level guidelines signify that they are based on expert consensus. This includes all the topics touched upon, all selected after a Delphi procedure among the experts/authors and edited into a coherent whole providing an overview of the subject. Certain passages have been adopted without changes from the previous version. The treatment of the disease and potential treatment complications are not included, being beyond the scope of this guidelines part. Results: Since the S1 guidelines publication, the literature on HS management has grown rapidly, enabling the current revision. The expansion of the guideline is evident and signifies a major leap forward in HS management. Conclusions: The first part of the guideline for HS provides a consensus‐based advice aimed at improving the health care of patients with HS at a generalist level through expert advice.
- 18 August 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Open AccessEuropean S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment
Background: This first part of the S2k guidelines is an update of the 2015 S1 European guidelines based on the structured assessment of clinically relevant topics by the panel of experts. It is complemented by Part 2, which deals with treatments. Objectives: These guidelines aim to provide the generalist with expert guidance regarding clinically relevant topics such as, for example, diagnosis, clinimetrics and comorbidities. Methods: The S2k level guidelines signify that they are based on expert consensus. This includes all the topics touched upon, all selected after a Delphi procedure among the experts/authors and edited into a coherent whole providing an overview of the subject. Certain passages have been adopted without changes from the previous version. The treatment of the disease and potential treatment complications are not included, being beyond the scope of this guidelines part. Results: Since the S1 guidelines publication, the literature on HS management has grown rapidly, enabling the current revision. The expansion of the guideline is evident and signifies a major leap forward in HS management. Conclusions: The first part of the guideline for HS provides a consensus‐based advice aimed at improving the health care of patients with HS at a generalist level through expert advice.
- Open Access
- 16 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Exploring the Impact of Fatigue and Sleep Disturbance in Hidradenitis Suppurativa: Perspectives from Patients and Healthcare Professionals
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that affects physical, social and emotional aspects of life for people living with HS (plwHS). Although many plwHS consider pain the most bothersome symptom, fatigue and sleep disturbance are underexplored in research and rarely discussed in clinical practice. This article shares perspectives from plwHS and people working with patients, including healthcare professionals (HCPs), from Europe and North America, on the impact of HS-related fatigue and sleep disturbance on quality of life (QoL). Fatigue was described as a debilitating symptom affecting QoL, with HCPs often noting that plwHS were unaware of the full impact of fatigue until treatment improved their HS symptoms. Sleep disturbance was mainly attributed to HS-related pain, pruritus and lesion drainage, with sleep deficits accumulating over time. The strain of HS impacted personal relationships, with plwHS expressing less interest in social interactions or intimate relationships, leading to feelings of guilt, failure, isolation and reduced self-esteem. Fatigue and sleep disturbance also affected work productivity, and consequently, career progression and financial stability. Recognizing the multifaceted HS symptoms, providing reasonable adjustments in the workplace, encouraging open dialogue with HCPs and measuring fatigue with a validated instrument could help improve QoL of plwHS.
- 16 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessExploring the Impact of Fatigue and Sleep Disturbance in Hidradenitis Suppurativa: Perspectives from Patients and Healthcare Professionals
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that affects physical, social and emotional aspects of life for people living with HS (plwHS). Although many plwHS consider pain the most bothersome symptom, fatigue and sleep disturbance are underexplored in research and rarely discussed in clinical practice. This article shares perspectives from plwHS and people working with patients, including healthcare professionals (HCPs), from Europe and North America, on the impact of HS-related fatigue and sleep disturbance on quality of life (QoL). Fatigue was described as a debilitating symptom affecting QoL, with HCPs often noting that plwHS were unaware of the full impact of fatigue until treatment improved their HS symptoms. Sleep disturbance was mainly attributed to HS-related pain, pruritus and lesion drainage, with sleep deficits accumulating over time. The strain of HS impacted personal relationships, with plwHS expressing less interest in social interactions or intimate relationships, leading to feelings of guilt, failure, isolation and reduced self-esteem. Fatigue and sleep disturbance also affected work productivity, and consequently, career progression and financial stability. Recognizing the multifaceted HS symptoms, providing reasonable adjustments in the workplace, encouraging open dialogue with HCPs and measuring fatigue with a validated instrument could help improve QoL of plwHS.
- Open Access
- 23 January 2026
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (3) , 846-853
Experiences of Drainage and Associated Impacts: A Qualitative Study Among Patients With Hidradenitis Suppurativa
Background: Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin condition often accompanied by malodorous drainage. Drainage affects quality of life, contributing to stigma, emotional distress, and physical challenges. Recognising the role of drainage in HS, the HiSTORIC (Hidradenitis SuppuraTiva cORe outcomes set International Collaboration) initiative identified it as a key symptom in clinical trials and developed the The HIdradenitis suppurativa DrainagE (HIDE) Scale. Objectives: This study aimed to explore patients' experiences of drainage to guide person‐centred care approaches. Methods: A qualitative secondary analysis was conducted using data from the parent study on The HIDE Scale ©️ . The data included 38 interviews with patients aged ≥ 18 years, diagnosed with HS, and experiencing drainage. Reflexive thematic analysis was applied using an inductive and semantic approach, guided by person‐centred theoretical perspectives. Results: Three overarching themes emerged: (1) Drainage is difficult to explain due to its unpredictable and complex nature; (2) Drainage impacts mental well‐being , contributing to feelings of social stigma, frustration, and emotional distress; and (3) Drainage involves significant physical difficulties , including malodour, frequent dressing changes, and daily activity disruption. Patients described drainage by volume, consistency, colour, and location, emphasising its multidimensional impact. Despite these challenges, pain was identified as the most debilitating symptom of HS. Conclusions: This study highlights the physical, psychological, and social impact of drainage in HS, emphasising its complexity and unpredictability. Patients described drainage as a multifaceted experience that profoundly affects their quality of life. To improve care, healthcare providers should integrate an assessment of drainage into clinical practice, utilising standardised tools like The HIDE Scale ©️ . Addressing physical and psychosocial aspects of drainage through open and empathetic discussions can reduce stigma, foster a sense of support, and enhance patient–clinician relationships. Adopting person‐centred approaches validates patients' experiences and holistic assessment is essential for improving care strategies and the well‐being of individuals living with HS.
- 23 January 2026
- Published by Wiley in JEADV Clinical Practice
- Vol. 5 (3) , 846-853
Open AccessExperiences of Drainage and Associated Impacts: A Qualitative Study Among Patients With Hidradenitis Suppurativa
Background: Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin condition often accompanied by malodorous drainage. Drainage affects quality of life, contributing to stigma, emotional distress, and physical challenges. Recognising the role of drainage in HS, the HiSTORIC (Hidradenitis SuppuraTiva cORe outcomes set International Collaboration) initiative identified it as a key symptom in clinical trials and developed the The HIdradenitis suppurativa DrainagE (HIDE) Scale. Objectives: This study aimed to explore patients' experiences of drainage to guide person‐centred care approaches. Methods: A qualitative secondary analysis was conducted using data from the parent study on The HIDE Scale ©️ . The data included 38 interviews with patients aged ≥ 18 years, diagnosed with HS, and experiencing drainage. Reflexive thematic analysis was applied using an inductive and semantic approach, guided by person‐centred theoretical perspectives. Results: Three overarching themes emerged: (1) Drainage is difficult to explain due to its unpredictable and complex nature; (2) Drainage impacts mental well‐being , contributing to feelings of social stigma, frustration, and emotional distress; and (3) Drainage involves significant physical difficulties , including malodour, frequent dressing changes, and daily activity disruption. Patients described drainage by volume, consistency, colour, and location, emphasising its multidimensional impact. Despite these challenges, pain was identified as the most debilitating symptom of HS. Conclusions: This study highlights the physical, psychological, and social impact of drainage in HS, emphasising its complexity and unpredictability. Patients described drainage as a multifaceted experience that profoundly affects their quality of life. To improve care, healthcare providers should integrate an assessment of drainage into clinical practice, utilising standardised tools like The HIDE Scale ©️ . Addressing physical and psychosocial aspects of drainage through open and empathetic discussions can reduce stigma, foster a sense of support, and enhance patient–clinician relationships. Adopting person‐centred approaches validates patients' experiences and holistic assessment is essential for improving care strategies and the well‐being of individuals living with HS.
- 21 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 912-915
Seeking Role Models for Hidradenitis Suppurativa: From Historical Figures to Modern Advocates
- 21 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 912-915
Seeking Role Models for Hidradenitis Suppurativa: From Historical Figures to Modern Advocates
- Top Cited PapersOpen Access
- 19 December 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5) , 899-941
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
Introduction: This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.Objective: These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).Methods: The chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.Results: Since the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non‐inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non‐inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5‐day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate‐to‐severe HS. Various surgical procedures are available for the predominantly non‐inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.Conclusions: Suitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.
- 19 December 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5) , 899-941
Top Cited PapersOpen AccessEuropean S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
Introduction: This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.Objective: These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).Methods: The chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.Results: Since the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non‐inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non‐inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5‐day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate‐to‐severe HS. Various surgical procedures are available for the predominantly non‐inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.Conclusions: Suitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.